Keywords: Ph +; AS; activation segment; CS or C-spine; catalytic spine; CL; catalytic loop; CTT; carboxyterminal tail; D1; immunoglobulin-like domain-1; EGFR; epidermal growth factor receptor; GIST; gastrointestinal stromal tumors; GK; gatekeeper; GRL; Gly-rich loop; KD;
مقالات ISI Ph + (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Ph +; Acute lymphoblastic leukemia; ALL; Allogeneic; Cytogenetics; Dasatinib; Imatinib; Minimal residual disease; MRD; Nilotinib; Philadelphia chromosome positive; Ph+; Ponatinib; Stem cell transplant; TKI; Tyrosine kinase inhibitor;
Keywords: Ph +; Acute lymphoblastic leukemia; Chronic myeloid leukemia; Ph+; Relapse; TKIs;
Keywords: Ph +; Afatinib (PubMed CID: 10184653); Crizotinib (PubMed CID: 11626560); Erlotinib (PubMed CID: 176870); Gefitinib (PubMed CID: 123631); Imatinib (PubMed CID: 5291); Nilotinib (PubMed CID: 644241); Sorafinib (PubMed CID: 216239); Sunitinib (PubMed CID: 5329102
Keywords: Ph +; AKAP; A-Kinase Anchoring Protein; ALL; acute lymphoblastic leukemia; A.S.; activation segment; CDK; cyclin-dependent kinase; CML; chronic myelogenous leukemia; C-spine; catalytic spine; EGFR; epidermal growth factor receptor; FGFR; fibroblast growth facto
BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells
Keywords: Ph +; ABL; Abelson kinase; ALL; acute lymphoblastic leukemia; BCR; break clustering region; CML; chronic myeloid leukemia; DST; dasatinib; IMT; imatinib; NRT; nirotinib; Ph+; Philadelphia chromosome positive; TKI; tyrosine kinase inhibitor; Ph+ ALL; Imatinib-re
Abnormal hematopoiesis and autoimmunity in human subjects with germline IKZF1 mutations
Keywords: Ph +; Acute lymphoblastic leukemia; autoimmune disease; B-cell deficiency; common lymphoid progenitor; DNA binding; dysgammaglobulinemia; germline mutation; Ikaros; IKZF1; nuclear localization; BCP-ALL; B-cell precursor acute lymphoblastic leukemia; CLP; Common
Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma
Keywords: Ph +; ALL; acute lymphoblastic leukemia; BCR-ABL; breakpoint cluster region-Abelson murine leukemia viral oncogene homolog; CML; chronic myeloid leukemia; CYP3A4; cytochrome P450 3A4; DMP; N-desmethyl ponatinib; ESI; electrospray Ionization; FVB; friend leukemi
Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
Keywords: Ph +; Philadelphia chromosome positive; Ph+; Additional cytogenetic abnormalities; Monosomy 7; Allogeneic; Stem cell transplant
Ab initio study on the low-lying excited states of gas-phase PH+ cation including spin–orbit coupling
Keywords: Ph +; MRCI+Q; Potential energy curve (PEC); Spectroscopic constants; PH+
Clinical and Laboratory Biology of Childhood Acute Lymphoblastic Leukemia
Keywords: Ph +; ALL; Acute lymphoblastic leukemia; CNS; Central nervous system; COG; Children's Oncology Group; CRLF2; Cytokine receptor-like factor 2; CRT; Cranial radiation therapy; EFS; Event-free survival; MLL; Mixed-lineage leukemia; MRD; Minimal residual disease;
Theoretical study on the reaction of PH+ with H2O
Keywords: Ph +; PH+; Density function theory; Reaction mechanism; Potential energy surface;
The anti-leukemic efficacy of the third generation bisphosphonate ONO5920/YM529
Keywords: Ph +; YM529; ONO5920/YM529; BP; bisphosphonate; P-gp; P-glycoprotein; DNR; daunorubicin; PAM; pamidronate; ZOL; zoledronic acid; Ph+; philadelphia chromosome positive; Ara-C; cytarabine; MDR; multidrug-resistant; FCS; fetal calf serum; CML; chronic myelogeneous